Axsome Therapeutics, Inc.
AXSM
$118.51
$1.371.17%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 69.83% | 72.16% | 42.53% | 51.47% | 59.73% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 69.83% | 72.16% | 42.53% | 51.47% | 59.73% |
| Cost of Revenue | 49.27% | 48.33% | 27.77% | 51.76% | 85.08% |
| Gross Profit | 72.04% | 74.77% | 44.11% | 51.45% | 57.41% |
| SG&A Expenses | 23.46% | 24.51% | 27.31% | 29.24% | 45.79% |
| Depreciation & Amortization | -0.30% | -0.27% | 0.27% | 0.27% | 0.28% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 27.06% | 35.34% | 40.71% | 43.96% | 60.37% |
| Operating Income | 20.53% | 2.38% | -38.01% | -34.76% | -61.08% |
| Income Before Tax | 19.96% | 6.65% | -20.50% | -55.22% | -69.63% |
| Income Tax Expenses | 12.76% | 105.25% | -91.15% | -125.29% | -151.10% |
| Earnings from Continuing Operations | 19.98% | 6.11% | -20.05% | -54.07% | -67.28% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 19.98% | 6.11% | -20.05% | -54.07% | -67.28% |
| EBIT | 20.53% | 2.38% | -38.01% | -34.76% | -61.08% |
| EBITDA | 21.60% | 2.98% | -38.85% | -35.62% | -63.34% |
| EPS Basic | 22.16% | 9.65% | -15.29% | -44.44% | -52.20% |
| Normalized Basic EPS | 20.78% | 5.15% | -30.95% | -24.35% | -41.01% |
| EPS Diluted | 22.09% | 9.58% | -15.29% | -44.44% | -52.20% |
| Normalized Diluted EPS | 20.78% | 5.15% | -30.95% | -24.35% | -41.01% |
| Average Basic Shares Outstanding | 2.95% | 4.11% | 5.51% | 7.13% | 9.90% |
| Average Diluted Shares Outstanding | 2.95% | 4.11% | 5.51% | 7.13% | 9.90% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |